The antitumor efficacy of the DC vaccine is believed to be impeded by the immunosuppressive tumor microenvironment, which suppresses antigen cross-presentation and the activity of antigen-specific CD8+ and CD4+ T-lymphocytes within the tumor stroma [105]. This evidence concerns the gene CD8A and neoplasm.